Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation

Future Cardiology

Volumn 7, Issue 6, 2011, Pages 733-737

  Burashnikov, Alexander ^a   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

antiarrhythmic drugs; cardiac arrhythmias; electrophysiology; pharmacology; sodium channel blockers

Indexed keywords

AMIODARONE; FLECAINIDE; PROPAFENONE; RANOLAZINE;

ARTICLE; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MULTICENTER STUDY (TOPIC); POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUPRAVENTRICULAR TACHYCARDIA; TOXICITY; UNSPECIFIED SIDE EFFECT;

EID: 80555144228     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.67     Document Type: Article

References (32)

1. Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am. J. Cardiol. 108(5), 673-676 (2011).
2. Cox JL. A perspective of postoperative atrial fibrillation in cardiac operations. Ann. Thorac. Surg. 56, 405-409 (1993).
3. Mathew JP, Fontes ML, Tudor IC et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 291, 1720-1729 (2004).
4. Kowey PR, Stebbins D, Igidbashian L et al. Clinical outcome of patients who develop PAF after CABG surgery. Pacing Clin. Electrophysiol. 24, 191-193 (2001).
5. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC).Eur. Heart J. 12, 1360-1420 (2010).
6. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol. 84, R20-R28 (1999).
7. Burashnikov A, Di Diego JM, Sicouri S et al. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm 5, 1735-1742 (2008).
8. Singh BN. Amiodarone: A multifaceted antiarrhythmic drug. Curr. Cardiol. Rep. 8, 349-355 (2006).
9. Goldschlager N, Epstein AE, Naccarelli GV et al. A practical guide for clinicians who treat patients with amiodarone. Heart Rhythm 4, 1250-1259 (2007).
10. Fuster V, Ryden LE, Cannom DS et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J. Am. Coll. Cardiol. 57, e101-e198 (2011).
11. Sicouri S, Moro S, Litovsky SH, Elizari MV, Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J. Cardiovasc. Electrophysiol. 8, 1269-1279 (1997).
12. Kirchhof P, Degen H, Franz MR et al. Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation. J. Pharmacol. Exp. Ther. 305, 257-263 (2003).
13. Ashikaga K, Kobayashi T, Kimura M et al. Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model. Eur. J. Pharmacol. 536, 148-153 (2006).
14. Antzelevitch C, Belardinelli L, Zygmunt AC et al. Electrophysiologic effects of ranolazine: A novel anti-anginal agent with antiarrhythmic properties. Circulation 110, 904-910 (2004).
15. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116, 1449-1457 (2007).
16. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiological basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 8, 1281-1290 (2011).
17. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 5, 1019-1026 (2008).
18. Kumar K, Nearing BD, Carvas M et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J. Cardiovasc. Electrophysiol. 20, 796-802 (2009).
19. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of dronedarone and ranolazine to suppress atrial fibrillation. J. Am. Coll. Cardiol. 56, 1216-1224 (2010).
20. Song Y, Shryock JC, Belardinelli L. An increase of late sodium current induces delayed after depolarizations and sustained triggered activity in atrial myocytes. Am. J. Physiol. Heart Circ. Physiol. 294, H2031-H2039 (2008).
21. Song Y, Shryock JC, Belardinelli L. A slowly inactivating sodium current contributes to spontaneous diastolic depolarization of atrial myocytes. Am. J. Physiol. Heart Circ. Physiol. 297, H1254-H1262 (2009).
22. Scirica BM, Morrow DA, Hod H et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116, 1647-1652 (2007).
23. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol. J. 8, 175-181 (2008).
24. Murdock DK, Kersten M, Kaliebe J, Larrian G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: A reveiw of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol. J. 9, 260-267 (2009).
25. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The Ranolazine Open Label Experience (ROLE).J. Am. Coll. Cardiol. 49, 1027-1034 (2007).
26. Wilson SR, Scirica BM, Braunwald E et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J. Am. Coll. Cardiol. 53, 1510-1516 (2009).
27. Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N. Engl. J. Med. 351, 2384-2391 (2004).
28. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 355, 251-259 (2006).
29. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 355, 260-269 (2006).
30. De Ferrari GM, Klersy C, Ferrero P et al. Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur. J. Heart Fail. 9, 502-509 (2007).
31. Lee DS, Gona P, Vasan RS et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 119, 3070-3077 (2009).
32. Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ. Arrhythm. Electrophysiol. 3, 88-95 (2010).